Exhaled Breath Analysis for Lung Cancer Detection: From VOCs Signatures to EBC-Based Liquid Biopsy and Clinical Translation.
5 affiliations
- 1Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China.
- 2Thoracic Oncology Institute, Peking University People's Hospital, Beijing, China.
- 3Research Unit of Intelligence Diagnosis and Treatment in Early Non-Small Cell Lung Cancer, Chinese Academy of Medical Sciences, 2021RU002, Beijing, China.
- 4Institute of Advanced Clinical Medicine, Peking University, Beijing, China.
- 5Frontiers Science Center for Cancer Integrative Omics, Peking University People's Hospital, Beijing, China.
Abstract
Lung cancer remains the leading cause of cancer-related mortality globally. Although low-dose computed tomography (LDCT) is the current standard for early screening, its high false-positive rates and cumulative radiation exposure create a pressing clinical need for complementary, non-invasive diagnostic tools. Exhaled breath analysis represents an accessible strategy for early detection and risk stratification. Early breathomics primarily focused on gas-phase volatile organic compounds (VOCs). However, as volatile metabolites, VOCs are chemically unstable and highly susceptible to background ambient air and physiological confounders. Distinct from gas-phase analysis, exhaled breath condensate (EBC) offers enhanced biomarker stability and functions as a lung-proximal liquid biopsy. By capturing non-volatile, high-molecular-weight analytes, including tumor-derived nucleic acids and proteins, EBC more closely reflects the underlying molecular mechanisms of the respiratory microenvironment. Nevertheless, the clinical translation of EBC remains constrained by severe sample dilution, unstandardized collection device architectures, and pre-analytical inconsistencies. This review summarizes the progression from VOCs profiling to EBC-based platforms, detailing recent advances in sample harvesting, ultrasensitive detection technologies, and multi-omics integration. Advancing EBC toward routine clinical use requires consensus-driven standard operating procedures and the application of machine learning algorithms to high-dimensional datasets. Future efforts should prioritize large-scale, multicenter prospective trials to validate specific EBC signatures, thereby establishing this technology as a reliable liquid biopsy for precision pulmonary oncology.
Related
- Elevated carbon dioxide in exhaled breath induces false-positive DOB results during Helicobacter pylori detection with ¹³C-urea breath test using infrared spectroscopy.
- Exhaled Breath Temperature in COPD
- Non-invasive quantification of lower airway antigen-specific antibodies using exhaled breath particles – an observational proof-of-concept study
- Assessment of Immune and Proteomic Markers in Exhaled Breath Condensate: A Feasibility Study.
- Exhaled breath patterns following tumour resection in patients with non-small cell lung cancer
BibTeX
@article{sun2026exhaled,
title = {{Exhaled Breath Analysis for Lung Cancer Detection: From VOCs Signatures to EBC-Based Liquid Biopsy and Clinical Translation.}},
author = {Penghai Sun and Zhenkai Fu and Shaodong Wang and Yun Li and Mantang Qiu},
journal = {Thoracic cancer},
year = {2026},
month = oct,
doi = {10.1111/1759-7714.70404},
url = {https://europepmc.org/article/MED/42896885},
note = {CC BY},
}
RIS
TY - JOUR
TI - Exhaled Breath Analysis for Lung Cancer Detection: From VOCs Signatures to EBC-Based Liquid Biopsy and Clinical Translation.
AU - Penghai Sun
AU - Zhenkai Fu
AU - Shaodong Wang
AU - Yun Li
AU - Mantang Qiu
PY - 2026
DA - 2026/10/01
JO - Thoracic cancer
DO - 10.1111/1759-7714.70404
UR - https://europepmc.org/article/MED/42896885
AB - Lung cancer remains the leading cause of cancer-related mortality globally. Although low-dose computed tomography (LDCT) is the current standard for early screening, its high false-positive rates and cumulative radiation exposure create a pressing clinical need for complementary, non-invasive diagnostic tools. Exhaled breath analysis represents an accessible strategy for early detection and risk stratification. Early breathomics primarily focused on gas-phase volatile organic compounds (VOCs). However, as volatile metabolites, VOCs are chemically unstable and highly susceptible to background ambient air and physiological confounders. Distinct from gas-phase analysis, exhaled breath condensate (EBC) offers enhanced biomarker stability and functions as a lung-proximal liquid biopsy. By capturing non-volatile, high-molecular-weight analytes, including tumor-derived nucleic acids and proteins, EBC more closely reflects the underlying molecular mechanisms of the respiratory microenvironment. Nevertheless, the clinical translation of EBC remains constrained by severe sample dilution, unstandardized collection device architectures, and pre-analytical inconsistencies. This review summarizes the progression from VOCs profiling to EBC-based platforms, detailing recent advances in sample harvesting, ultrasensitive detection technologies, and multi-omics integration. Advancing EBC toward routine clinical use requires consensus-driven standard operating procedures and the application of machine learning algorithms to high-dimensional datasets. Future efforts should prioritize large-scale, multicenter prospective trials to validate specific EBC signatures, thereby establishing this technology as a reliable liquid biopsy for precision pulmonary oncology.
SN - 1759-7706
SN - 1759-7714
ER -